Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul:20:37-47.
doi: 10.1016/j.euros.2020.06.006.

Genetic Landscape of Prostate Cancer Conspicuity on Multiparametric Magnetic Resonance Imaging: A Systematic Review and Bioinformatic Analysis

Affiliations
Review

Genetic Landscape of Prostate Cancer Conspicuity on Multiparametric Magnetic Resonance Imaging: A Systematic Review and Bioinformatic Analysis

Joseph M Norris et al. Eur Urol Open Sci. 2020 Jul.

Abstract

Context: Multiparametric magnetic resonance imaging (mpMRI) detects most, but not all, clinically significant prostate cancer. The genetic basis of prostate cancer visibility and invisibility on mpMRI remains uncertain.

Objective: To systematically review the literature on differential gene expression between mpMRI-visible and mpMRI-invisible prostate cancer, and to use bioinformatic analysis to identify enriched processes or cellular components in genes validated in more than one study.

Evidence acquisition: We performed a systematic literature search of the Medline, EMBASE, PubMed, and Cochrane databases up to January 2020 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. The primary endpoint was differential genetic features between mpMRI-visible and mpMRI-invisible tumours. Secondary endpoints were explanatory links between gene function and mpMRI conspicuity, and the prognostic value of differential gene enrichment.

Evidence synthesis: We retrieved 445 articles, of which 32 met the criteria for inclusion. Thematic synthesis from the included studies showed that mpMRI-visible cancer tended towards enrichment of molecular features associated with increased disease aggressivity, including phosphatase and tensin homologue (PTEN) loss and higher genomic classifier scores, such as Oncotype and Decipher. Three of the included studies had accompanying publicly available data suitable for further bioinformatic analysis. An over-representation analysis of these datasets revealed increased expression of genes associated with extracellular matrix components in mpMRI-visible tumours.

Conclusions: Prostate cancer that is visible on mpMRI is generally enriched with molecular features of tumour development and aggressivity, including activation of proliferative signalling, DNA damage, and inflammatory processes. Additionally, there appears to be concordant cellular components and biological processes associated with mpMRI conspicuity, as highlighted by bioinformatic analysis of large genetic datasets.

Patient summary: Prostate cancer that is detected by magnetic resonance imaging (MRI) tends to have genetic features that are associated with more aggressive disease. This suggests that MRI can be used to assess the likelihood of aggressive prostate cancer, based on tumour visibility.

Keywords: Bioinformatic analysis; Genetics; Genomics; Multiparametric magnetic resonance imaging; Prostate cancer; Systematic review.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
PRISMA flow diagram of evidence acquisition. PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-analyses.
Fig. 2
Fig. 2
Bioinformatic synthesis of included studies. (A) Venn diagram of genetic overlap for mpMRI conspicuity–associated genes and (B–D) chord diagrams for each study (studies by Houlahan et al , Li et al , and Stoyanova et al , respectively) illustrating over-representation analysis of significant differentially expressed genes identified in each study and over-represented cellular component gene ontology terms associated with these genes. mpMRI = multiparametric magnetic resonance imaging.

Similar articles

Cited by

References

    1. Ahmed H.U., El-Shater Bosaily A., Brown L.C. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815–822. - PubMed
    1. Houlahan K.E., Salmasi A., Sadun T.Y. Molecular hallmarks of multiparametric magnetic resonance imaging visibility in prostate cancer. Eur Urol. 2019;76:18–23. - PMC - PubMed
    1. Bill-Axelson A., Holmberg L., Garmo H. Radical prostatectomy or watchful waiting in prostate cancer—29-year follow-up. N Engl J Med. 2018;379:2319–2329. - PubMed
    1. Fraser M., Sabelnykova V.Y., Yamaguchi T.N. Genomic hallmarks of localized, non-indolent prostate cancer. Nature. 2017;541:359–364. - PubMed
    1. Norris J.M., Simpson B.S., Parry M.A. Genetic correlates of prostate cancer visibility (and invisibility) on multiparametric magnetic resonance imaging: it's time to take stock. BJU Int. 2020;125:340–342. - PubMed